A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndrome.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 28 02 2022
accepted: 09 05 2022
medline: 28 3 2023
pubmed: 13 7 2022
entrez: 12 7 2022
Statut: ppublish

Résumé

To determine whether early damage and its kinetics measured by the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality. We carried out a single-centre retrospective analysis of thrombotic APS patients (2006 Sydney criteria), using the DIAPS for damage assessment. Early damage was considered to be at six months after disease onset; early damage increase (delta-DIAPS) was deemed to be at least a one-point rise in DIAPS within the first five years of illness. Groups were compared using appropriate statistical tests. Survival was analysed by the Kaplan-Meier method. Cox regression analysis was performed to investigate predictors of mortality. A total of 197 patients (71.1% female; 65.9% primary APS; 72.4% Caucasian) were followed for up to 43 years (median 10). Damage developed in 143 (73.6%) patients. Twenty-three patients (12%) died. Secondary APS (HR 3.07, 95%CI 1.32-7.12, p=0.009), male sex (HR 3.14, 95%CI 1.35-7.33, p=0.008) and age at APS onset ≥40 years (HR 5.34, 95%CI 1.96-14.53, p=0.001) were risk factors for death. Early damage (n=69, 35.0%) was not associated with death (p=0.231). Having a first arterial event was associated with early damage (p<0.001), but not with delta-DIAPS (p=0.539) nor with the risk of death (p=0.151). Delta-DIAPS (n=53/181, 29.3%) predicted mortality (HR 5.40, 95%CI 2.33-12.52, p<0.001), even after adjusting individually for APS category (secondary), sex (male), early damage and age at APS onset (≥40 years) (all p<0.005). Evolving damage in the first five years of illness, but not early damage, predicted mortality regardless of the nature of the first thrombotic event, sex, APS category and age.

Identifiants

pubmed: 35819804
pii: 18493
doi: 10.55563/clinexprheumatol/0gs167
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

605-612

Auteurs

Pedro Gaspar (P)

Department of Internal Medicine 2, North Lisbon University Hospital Centre, Lisbon, and Instituto de Medicina Molecular João Lobo Antunes, Faculty of Medicine, University of Lisbon, Portugal. pedrosilvagaspar@gmail.com.

Filipa Farinha (F)

Centre for Rheumatology, Division of Medicine, University College London, UK.

Zara Sayar (Z)

Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.

Maria Efthymiou (M)

Haemostasis Research Unit, Department of Haematology, University College London, UK.

Hannah Cohen (H)

Department of Haematology, University College London Hospitals NHS Foundation Trust, London, and Haemostasis Research Unit, Department of Haematology, University College London, UK.

David A Isenberg (DA)

Centre for Rheumatology, Division of Medicine, University College London, and Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH